{"id":235926,"date":"2026-04-25T22:10:48","date_gmt":"2026-04-26T03:10:48","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/04\/treatment-of-follicular-lymphoma-with-chop-and-anti-cd20-therapy"},"modified":"2026-04-25T22:10:48","modified_gmt":"2026-04-26T03:10:48","slug":"treatment-of-follicular-lymphoma-with-chop-and-anti-cd20-therapy","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/04\/treatment-of-follicular-lymphoma-with-chop-and-anti-cd20-therapy","title":{"rendered":"Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/treatment-of-follicular-lymphoma-with-chop-and-anti-cd20-therapy.jpg\"><\/a><\/p>\n<p>Fifteen-year follow-up from the SWOG S0016 trial indicates that a subset of patients with advanced-stage FollicularLymphoma can achieve cure after first-line chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and anti-CD20 therapy.<\/p>\n<p>Cure modeling estimated an overall cure rate of 42%, with relapse rates substantially declining over time and highest cure likelihood in patients with low Follicular Lymphoma International Prognostic Index scores and normal \u03b22 microglobulin levels.<\/p>\n<hr>\n<p>This secondary analysis examines 15-year follow-up data from a randomized clinical trial to evaluate the potential for long-term remission and cure for follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin\/doxorubicin, oncovin, and prednisone\/prednisolone (CHOP)\u2013based regimens.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fifteen-year follow-up from the SWOG S0016 trial indicates that a subset of patients with advanced-stage FollicularLymphoma can achieve cure after first-line chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and anti-CD20 therapy. Cure modeling estimated an overall cure rate of 42%, with relapse rates substantially declining over time and highest cure likelihood in patients with low Follicular [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-235926","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/235926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=235926"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/235926\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=235926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=235926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=235926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}